A retrospective study assessing the incidence, morphology and severity of distinct purpuric eruptions (dermatological adverse event) associated with CPX-351/Vyxeos in patients of Acute Myeloid Leukemia
Latest Information Update: 10 Feb 2021
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
Most Recent Events
- 10 Feb 2021 New trial record
- 01 Feb 2021 Results published in the Journal of the American Academy of Dermatology